沙库巴曲缬沙坦钠联合β-受体阻滞剂治疗老年慢性心力衰竭患者的临床效果

赵世佳

[摘要] 目的 觀察老年慢性心力衰竭患者应用沙库巴曲缬沙坦钠联合β-受体阻滞剂治疗的临床效果。 方法 选取2015年10月至2019年10月我院收治的老年慢性心力衰竭患者76例，随机分为对照组和试验组，每组各38例。对照组给予β-受体阻滞剂治疗，试验组给予沙库巴曲缬沙坦钠联合β-受体阻滞剂治疗。比较两组患者心功能相关指标，具体包括LVESD、LVEDD、LVEF及BNP，临床试验室指标（Gal-3、sST2、sICAM-1、GDF-15）及治疗的安全性、有效性。 结果 治疗后试验组患者LVESD、LVEDD及BNP显著低于对照组，差异有统计学意义（P<0.05）;试验组患者的LVEF显著高于对照组，差异有统计学意义（P<0.05）;试验组患者的Gal-3、sST2、sICAM-1及GDF-15显著低于对照组，差异有统计学意义（P<0.05）;试验组治疗总有效率显著高于对照组，差异有统计学意义（P<0.05）;两组治疗后不良反应总发生率比较，差异无统计学意义（P>0.05）。 结论 在老年慢性心力衰竭患者治疗中应用沙库巴曲缬沙坦钠联合β-受体阻滞剂治疗效果显著，且整体安全性高。

[关键词] 沙库巴曲缬沙坦钠;β-受体阻滞剂;老年慢性心力衰竭;心功能不全

[中图分类号] R541          [文献标识码] B          [文章编号] 1673-9701（2021）24-0050-04

Clinical efficacy on the treatment of elderly patients with chronic heart failure with sacubitril valsartan sodium combined with β-blockers

ZHAO Shijia

Department of Cardiovascular Internal Medicine， Huludao Center Hospital in Liaoning Province， Huludao   125000， China

[Abstract] Objective To analyze the observation on the clinical efficacy on the treatment of elderly patients with chronic heart failure with sacubitril valsartan sodium combined with β-blockers. Methods A total of 76 elderly patients with chronic heart failure admitted to our hospital from October 2015 to October 2019 were selected and randomly divided into the control group （n=38） and the experimental group （n=38）. The control group was treated with β-blockers， while the experimental group was treated with sacubitril valsartan sodium combined with β-blockers. The related indexes of cardiac function between patients in the two groups were compared， including the values of LVESD， LVEDD， LVEF and BNP， clinical laboratory index of Gal-3， sST2， sICAM-1 and GDF-15， as well as the safety and efficacy of the treatment. Results The values of LVESD， LVEDD and BNP in the experimental group were significantly lower than those in the control group， with significant difference （P<0.05）. The LVEF of patients in the experimental group was significantly higher than that in the control group， with significant difference（P<0.05）. The values of Gal-3， sST2， sICAM-1 and GDF-15 of patients in the experimental group were significantly lower than those in the control group， with significant difference （P<0.05）. The total effective rate in the experimental group was significantly higher than that in the control group， with significant difference（P<0.05）， and there were no statistically significant differences in the total incidence of adverse reactions between the two groups after treatment （P>0.05）. Conclusion In the treatment of elderly patients with chronic heart failure， the application of sacubitril valsartan sodium combined with β-blockers has significant therapeutic efficacy and high overall safety.